Despite its unique ability to block sodium-glucose linked transporter 2 (SGLT2) in the kidneys and SGLT1 in the intestines, Lexicon’s Zynquista (sotagliflozin) has had difficulty negotiating ...

María Pilar Agustín-Llach [Opens in a new window] and The present study delves into the structure and lexical organization of L1 and L2 mental lexicons. Indirect access to the mental lexicon is ...

Lexicon (LXRX) announced that patient screening has been completed in the Phase 2b PROGRESS clinical trial evaluating the company’s AAK1 inhibitor, LX9211, for the treatment of Diabetic ...

Roanna Ruiz has given her Buy rating due to a combination of factors that highlight Lexicon Pharmaceuticals’ strategic advancements and potential for value growth. One significant reason is the ...